BofA analyst Michael Cherny lowered the firm’s price target on GoodRx to $8 from $9.50 and keeps a Buy rating on the shares. The firm is increasing its FY23 revenue and adjusted EBITDA estimates to reflect Q3 results, while decreasing its FY24 revenue and adjusted EBITDA estimates to reflect the uncertain variables around partnership programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDRX: